Sanofi S.A., FR0000120578

Sanofi stock carries 17.8 percent Q2 sales growth and a EUR 95 target

Published on 09/25/2026 at 12:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock traded at EUR 73.33 on September 24, 2026, while Deutsche Bank kept its Buy rating and EUR 95.00 target. Q2 business EPS rose 33.3 percent.

Modern pharmaceutical sterile fill-and-finish manufacturing facility interior with glass vial-filling machines and cleanroom workers in white suits — Sanofi FR0000120578 photorealistic sterile fill-and-finish facility with vial-filling machines and cleanroom workers, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) stock was trading at EUR 73.33 on Euronext Paris on September 24, 2026 at 9:23 a.m. CET, up 0.30 percent from the prior close. The latest earnings picture adds substance to the valuation debate: Q2 2026 net sales reached EUR 11.6 billion, up 17.8 percent year over year.

Q2 sales gain 17.8 percent

According to ScanX on September 18, 2026, Sanofi's Q2 net sales increased 17.8 percent to EUR 11.6 billion. The report also said business EPS grew 33.3 percent and business operating income rose 35.8 percent.

The comparison matters because earnings growth exceeded sales growth by 15.5 percentage points in the quarter. Sanofi therefore enters the second half of fiscal 2026 with operating leverage visible in the reported numbers, although the figures are business measures rather than GAAP results.

Deutsche Bank keeps EUR 95 target

According to Finanzen.ch on September 14, 2026, Deutsche Bank Research retained its Buy rating and EUR 95.00 price target for Sanofi. The bank cited results from the Lunsekimig asthma study presented at the ERS industry conference.

The target is EUR 21.67 above the September 24 price, which places the stated target 29.6 percent above the reference price. That gap frames the market's central question: whether newer pipeline assets can offset the longer-term pressure expected around Dupixent's patent cycle.

Q3 date is October 30

Marketscreener lists October 30, 2026 as the date for Sanofi's Q3 2026 results. The next report will test whether the 17.8 percent Q2 sales pace and 33.3 percent business EPS growth can continue into the second half.

Sanofi stock stays below target

Sanofi stock was trading at EUR 73.33 on Euronext Paris on September 24, 2026 at 9:23 a.m. CET, with a market capitalization of EUR 99.8 billion. The 0.30 percent daily gain was modest beside the EUR 95.00 analyst target and the latest double-digit operating figures.